MMP10 Promotes Efficient Thrombolysis After Ischemic Stroke in Mice with Induced Diabetes
Diabetes is an important risk factor for ischemic stroke (IS). Tissue-type plasminogen activator (tPA) has been associated with less successful revascularization and poor functional outcome in diabetes. We assessed whether a new thrombolytic strategy based on MMP10 was more effective than tPA in a murine IS model of streptozotocin (STZ)-induced diabetes. Wild-type mice were administered a single dose of streptozotocin (STZ) (180 mg/kg) to develop STZ-induced diabetes mellitus. Two weeks later, IS was induced by thrombin injection into the middle cerebral artery and the effect of recombinant MMP10 (6.5 μg/kg), tPA (10 mg/kg) or tPA/MMP10 on brain damage and functional outcome were analysed. Motor activity was assessed using the open field test. Additionally, we studied plasminogen activator inhibitor-1 (PAI-1) and thrombin-antithrombin complex levels (TAT) by ELISA and oxidative stress and blood-brain barrier (BBB) integrity by immunohistochemistry and western blot. MMP10 treatment was more effective at reducing infarct size and neurodegeneration than tPA 24 h and 3 days after IS in diabetic mice. Locomotor activity was impaired by hyperglycemia and ischemic injury, but not by the thrombolytic treatments. Additionally, TAT, oxidative stress and BBB permeability were reduced by MMP10 treatment, whereas brain bleeding or PAI-1 expression did not differ between treatments. Thrombolytic treatment with MMP10 was more effective than tPA at reducing stroke and neurodegeneration in a diabetic murine model of IS, without increasing haemorrhage. Thus, we propose MMP10 as a potential candidate for the clinical treatment of IS in diabetic patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Translational stroke research - 10(2019), 4 vom: 26. Aug., Seite 389-401 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Navarro-Oviedo, Manuel [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.01.2020 Date Revised 09.03.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12975-018-0652-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM286912023 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM286912023 | ||
| 003 | DE-627 | ||
| 005 | 20231225052822.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12975-018-0652-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0956.xml |
| 035 | |a (DE-627)NLM286912023 | ||
| 035 | |a (NLM)30051168 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Navarro-Oviedo, Manuel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MMP10 Promotes Efficient Thrombolysis After Ischemic Stroke in Mice with Induced Diabetes |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.01.2020 | ||
| 500 | |a Date Revised 09.03.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Diabetes is an important risk factor for ischemic stroke (IS). Tissue-type plasminogen activator (tPA) has been associated with less successful revascularization and poor functional outcome in diabetes. We assessed whether a new thrombolytic strategy based on MMP10 was more effective than tPA in a murine IS model of streptozotocin (STZ)-induced diabetes. Wild-type mice were administered a single dose of streptozotocin (STZ) (180 mg/kg) to develop STZ-induced diabetes mellitus. Two weeks later, IS was induced by thrombin injection into the middle cerebral artery and the effect of recombinant MMP10 (6.5 μg/kg), tPA (10 mg/kg) or tPA/MMP10 on brain damage and functional outcome were analysed. Motor activity was assessed using the open field test. Additionally, we studied plasminogen activator inhibitor-1 (PAI-1) and thrombin-antithrombin complex levels (TAT) by ELISA and oxidative stress and blood-brain barrier (BBB) integrity by immunohistochemistry and western blot. MMP10 treatment was more effective at reducing infarct size and neurodegeneration than tPA 24 h and 3 days after IS in diabetic mice. Locomotor activity was impaired by hyperglycemia and ischemic injury, but not by the thrombolytic treatments. Additionally, TAT, oxidative stress and BBB permeability were reduced by MMP10 treatment, whereas brain bleeding or PAI-1 expression did not differ between treatments. Thrombolytic treatment with MMP10 was more effective than tPA at reducing stroke and neurodegeneration in a diabetic murine model of IS, without increasing haemorrhage. Thus, we propose MMP10 as a potential candidate for the clinical treatment of IS in diabetic patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Fibrinolysis | |
| 650 | 4 | |a Matrix metalloproteinases | |
| 650 | 4 | |a Stroke, diabetes mellitus | |
| 650 | 4 | |a Thrombosis | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Tissue Plasminogen Activator |2 NLM | |
| 650 | 7 | |a EC 3.4.21.68 |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinase 10 |2 NLM | |
| 650 | 7 | |a EC 3.4.24.22 |2 NLM | |
| 700 | 1 | |a Roncal, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Salicio, Agustina |e verfasserin |4 aut | |
| 700 | 1 | |a Belzunce, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Rabal, Obdulia |e verfasserin |4 aut | |
| 700 | 1 | |a Toledo, Estefanía |e verfasserin |4 aut | |
| 700 | 1 | |a Zandio, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez, Jose A |e verfasserin |4 aut | |
| 700 | 1 | |a Páramo, Jose A |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Orbe, Josune |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Translational stroke research |d 2010 |g 10(2019), 4 vom: 26. Aug., Seite 389-401 |w (DE-627)NLM198739184 |x 1868-601X |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2019 |g number:4 |g day:26 |g month:08 |g pages:389-401 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12975-018-0652-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2019 |e 4 |b 26 |c 08 |h 389-401 | ||